Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> In this study, an immunosuppressive microenvironment was associated with high Lgr5 expression in GC.
|
31417548 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Several gastric stem cell (GSC) markers including CD44, CD133, and Lgr5 are upregulated in GC.
|
29084052 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An increased expression of LGR5 in primary GC correlated significantly with tumor regression.
|
31827644 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
At both the transcriptional and at the protein level, RNA-Seq and proteome analyses, respectively, revealed increased R-spondin expression in primed-MSC, and paracrine and juxtacrine mediated elevation of Lgr5 expression in GSC1, suggesting GSC-MSC-mediated support of cancer stemness in GSC1.
|
30379370 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we determined whether leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), known as a stem cell marker for colon cancer and gastric cancer, can serve as a novel GSC marker involved in EMT and a therapeutic target in glioma.
|
30208924 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the expression of L-PTGDS and PTGDR2 was negatively correlated with the GC-CSC markers Sall4 and Lgr5 in GC tissues.
|
29604141 |
2018 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, there was an inverse correlation between FOXO1 and GC stem cell marker LGR5 in human GC specimens.
|
28970066 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel Insights into Gastric Cancer: Methylation of R-spondins and Regulation of LGR5 by SP1.
|
28219935 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Flow cytometry demonstrated the presence of a variable fraction of Lgr5 in 19 out of 20 GC specimens.
|
28383763 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lgr5-specific siRNA could be designed into an effective therapeutic agent to inhibit gastric cancer angiogenesis.
|
28404940 |
2017 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
RNA in situ hybridization on tissue microarrays showed that 7 % of GCs were positive for LGR5.
|
26386561 |
2016 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
But interestingly, the expression of Lgr5 was associated with the age of GC patients (pooled OR=1.731, 95%CI=1.082-2.769, P=0.02) and Lauren type of GC (OR=2.284, 95%CI=1.611-3.238, P<0.001).
|
26077638 |
2016 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The disruption of tumor suppressors in Villin+ or Lgr5+ GSCs leads to GC in mouse models.
|
25574084 |
2015 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
In GC patients with active Hp infection, LPECs may be more susceptible to DNA damage than Lgr5-negative epithelial cells, suggesting that Hp infection may contribute to GC risk by affecting epithelial stem cells in the human stomach.
|
22945475 |
2013 |